Pfizer Inc.

NYSE:PFE  
41.49
-0.18 (-0.43%)
5:05:38 PM EDT: $41.51 +0.02 (+0.05%)
Products

Pfizer Inc Says U.S. FDA authorizes Pfizer COVID-19 Vaccine For Emergency Use

Published: 12/12/2020 04:31 GMT
Pfizer Inc. (PFE) - U.S. FDA Has Authorized Emergency Use of Mrna Vaccine, Bnt162b2, Against Covid-19 in Individuals 16 Years of Age Or Older.
Vaccine is Now Authorized Under an Emergency Use Authorization.
Under Operation Warp Speed, Dod in Partnership With Department of Hhs Will Manage Allocation, Distribution of Vaccine in U.S.preparing to File a Planned Biologics License Application (bla) With FDA for a Possible Full Regulatory Approval in 2021.
Plan to Provide an Option for Trial Participants Who Received Placebo to Receive Vaccine at Scheduled Timepoints in Study.companies Will Begin Delivering First Doses in U.S. Immediately, With Delivery Fulfillment Expected to Be Completed in 2021.
Pfizer and Biontech Expect to File a Biologics License Application for Possible Full Regulatory Approval in 2021.
Pfizer - Co and Biontech's Combined Manufacturing Network Has Potential to Supply Globally Up to 50 Million Vaccine Doses in 2020.
Pfizer - Co and Biontech's Combined Manufacturing Network Has Potential to Supply Up to 1.3 Billion Doses by End of 2021.